These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9350236)

  • 1. [Lung cancer].
    Furuse K
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1917-24. PubMed ID: 9350236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 3. [Developed new agents for lung cancer].
    Kato Y; Saijo N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy in metastatic non-small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):15-27. PubMed ID: 10981287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New chemotherapeutic agents for non-small cell lung cancer.
    Miller VA; Rigas JR; Grant SC; Pisters KM; Kris MG
    Chest; 1995 Jun; 107(6 Suppl):306S-311S. PubMed ID: 7781411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current perspectives of new agents in lung cancer].
    Fukuoka M
    Nihon Rinsho; 2000 May; 58(5):1103-10. PubMed ID: 10824557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gemcitabine].
    Takeda K
    Nihon Rinsho; 2002 May; 60 Suppl 5():359-65. PubMed ID: 12101689
    [No Abstract]   [Full Text] [Related]  

  • 9. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
    Morere JF
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S37-41. PubMed ID: 11924242
    [No Abstract]   [Full Text] [Related]  

  • 10. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
    Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising new agents in the treatment of non-small cell lung cancer.
    Edelman MJ; Gandara DR
    Cancer Chemother Pharmacol; 1996; 37(5):385-93. PubMed ID: 8599859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
    Calvo AR; Belani CP
    Cancer Treat Res; 2001; 105():189-227. PubMed ID: 11224988
    [No Abstract]   [Full Text] [Related]  

  • 13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
    Meert AP; Berghmans T; Branle F; Lemaître F; Mascaux C; Rubesova E; Vermylen P; Paesmans M; Sculier JP
    Anticancer Res; 1999; 19(5C):4379-90. PubMed ID: 10650780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?].
    Grossi F; de Marinis F; Frontini L; Gridelli C
    Tumori; 2008; 94(3):5-14. PubMed ID: 18705422
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation in locally advanced non-small cell lung cancer.
    Bonomi P; Shirazi W
    Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987
    [No Abstract]   [Full Text] [Related]  

  • 20. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.